Tre­vi’s mid-stage chron­ic cough da­ta meet ‘home run’ sce­nario, stock soars

Tre­vi Ther­a­peu­tics’ chron­ic cough drug re­duced pa­tients’ 24-hour cough fre­quen­cy by 57% com­pared to place­bo in a Phase 2a tri­al, ex­ceed­ing in­vestors’ ex­pec­ta­tions.

The com­pa­ny …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER